↑ 疾患リストへ ← 戻る

 56. ベーチェット病 [臨床試験数:41,薬物数:63(DrugBank:22),標的遺伝子数:33,標的パスウェイ数:32] 

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR19000271472020-01-014 November 2019Efficacy and safety of adalimumab in Behcet's disease-related uveitisEfficacy and safety of adalimumab in Behcet's disease-related uveitisBehcet's disease-related uveitis1:Adalimumab;State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen UniversityNot RecruitingBoth1:30;Phase 4China
2NCT04065672October 15, 201928 October 2019Low-dose IL-2 Treatment on Behcet's DiseaseLow-dose IL-2 Treatment on Behcet's DiseaseBehcet's DiseaseDrug: Low-dose IL-2Peking University People's HospitalNot recruiting18 Years70 YearsAll15Phase 2China
3NCT03771768May 25, 201923 April 2019Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's DiseaseActive Control,Randomized,Double- Blinded Clinical Trial of BDAutoimmune;Behcet SyndromeRadiation: Diode laser 980nm&100 mWatt;Drug: Triamcinolone AcetonideCairo UniversityNot recruiting18 Years60 YearsAll38N/A
4NCT03888846March 25, 201926 August 2019Topical Pentoxifylline Gel on Behcet's Disease Oral UlcersClinical Protocol for Administration of Topical Pentoxifylline Gel on Behcet's Disease Oral UlcersBehçet Disease Affecting Oral MucosaDrug: Pentoxifylline;Drug: ColchicineIpekyolu Ilac Ltd. StiIstanbul University-Cerrahpasa School of MedicineRecruiting18 YearsN/AAll60Phase 2Turkey
5NCT04022421October 1, 201829 July 2019Hydroxychloroquine Efficacy on Behcet's Disease ThrombosisThe Efficacy of Hydroxychloroquine on Behcet's Disease Thrombotic Events PreventionBehcet's Syndrome, Vascular TypeDrug: HydroxychloroquineAssiut UniversityRecruiting18 YearsN/AAll50N/AEgypt
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03522662August 1, 201811 June 2018Anti IL-18 (GSK1070806) in Behcet's DiseaseAn Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's DiseaseBehcet's DiseaseDrug: GSK1070806Cambridge University Hospitals NHS Foundation TrustNot recruiting18 YearsN/AAll12Phase 2United Kingdom
7NCT03371095March 15, 201812 March 2018Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet DiseaseMulticenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet DiseaseBehcet's Disease;VasculitisDrug: Infliximab;Drug: CyclophosphamideAssistance Publique - Hôpitaux de ParisNot recruiting12 YearsN/AAll52Phase 3
8NCT03274648October 201716 December 2017Dietary Interventions and Butyrate Production in Behçet's PatientsTherapeutic Modulation of Butyrate Production in Behçet's Patients: a Dietary Intervention TrialBehçEt DiseaseDietary Supplement: Oral butyrate;Dietary Supplement: Vegetarian diet;Dietary Supplement: Habitual dietAzienda Ospedaliero-Universitaria CareggiNot recruiting18 Years70 YearsAll30N/A
9NCT03209219June 30, 20172 July 2018Interferon a2a Versus Cyclosporine for Refractory Behçet`s Disease UveitisRandomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet`s Disease UveitisBehçet Disease;UveitisDrug: Cyclosporine Pill;Drug: Interferon Alfa-2AgwcmcRecruiting18 Years65 YearsAll36Phase 3China
10NCT02648581June 14, 201730 September 2019Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet DiseaseA Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet DiseaseBehçet DiseaseDrug: Subcutaneous UstekinumabAssistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/AAll16Phase 2France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11JPRN-UMIN0000254512017/04/0122 July 2019Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's diseaseClinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's diseaserefractory uveitis of Behcet's diseasePatients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year.Yokohama City University HospitalNot Recruiting20years-old65years-oldMale and Female5Not selectedJapan
12EUCTR2017-002264-41-FR28 February 2019NAEtude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Infliximab to that of Cyclophosphamide in severe Behçet's disease - ITACInduction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
MedDRA version: 20.0 Level: LLT Classification code 10004212 Term: Behcet's disease System Organ Class: 100000017240 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Remicade 100 mg
Product Name: Remicade 100 mg
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: infliximab
Other descriptive name: infliximab
Trade Name: cyclophosphamide
Product Name: cyclophosphamide
Pharmaceutical Form: Powder for solution for infusion
INN or Proposed INN: cyclophosphamide
Other descriptive name: cyclophosphamide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)Not Available Female: yes
Male: yes
52Phase 2France
13NCT02756650June 23, 20164 March 20191 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular InvolvementAn Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular InvolvementBehcet DiseaseDrug: drug administrationNovartis PharmaceuticalsRecruiting18 YearsN/AAll10Phase 2Turkey
14JPRN-UMIN0000200292016/04/0122 July 2019The significance of serum HBs-antigen as a monitoring examination for viral reactivation during immunesuppressive therapy in patients with previously resolved hepatitis B virus infectionThe significance of serum HBs-antigen as a monitoring examination for viral reactivation during immunesuppressive therapy in patients with previously resolved hepatitis B virus infection - Monitoring by HBs antigen for HBV ReactivationCollagen disease, collagen disease related disease, ulcerative colitis, Crohn's disease, intestinal Behcet's disease (simple ulcers included), psoriasis, and diseases that require other immunosuppressive therapies.Entecavir administration is initiated when serum HBV-DNA levels increased up to 3.0 Log/IU/mL and/or serum HBs-antigen becomes detectable.Saitama Medical UniversityRecruiting16years-oldNot applicableMale and Female300Not selectedJapan
15EUCTR2014-005390-36-GB17/02/201630 May 2016BIO BEHCET'S TRIALOptimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment. - BIO BEHÇET’SBehcets Disease
MedDRA version: 18.1 Level: LLT Classification code 10004212 Term: Behcet's disease System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Remicade
Product Name: Remicade
Product Code: 3400935113276
Pharmaceutical Form: Powder for infusion
INN or Proposed INN: infliximab
CAS Number: 170277-31-3
Current Sponsor code: PF-06438179
Concentration unit: g gram(s)
Concentration type: up to
Concentration number: 5-
Trade Name: Roferon-A, 3miu
Product Name: Roferon-A 3miu
Product Code: 8699505952864
Pharmaceutical Form: Solution for injection
INN or Proposed INN: alpha interferon
CAS Number: 9008-11-1
Concentration unit: million IU million international units
Concentration type: equal
Concentration number: 3-
Trade Name: Roferon-A, 4.5miu
Product Name: Roferon-A, 4.5miu
Product Code: J1081
Pharmaceutical Form: Suspension for injection
INN or Proposed INN: alpha interferon
Concentration unit: million IU million international units
Concentration type: equal
Concentration number: 4.5-
Trade Name: Roferon-A, 6miu
Product Name: Roferon-A, 6miu
Product Code: 2387066
Pharmaceutical Form: Solution for injection
INN or Proposed INN: alpha interferon
Concentration unit: million IU million international units
The University of LiverpoolAuthorisedFemale: yes
Male: yes
100Phase 3United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT02505568July 22, 201528 October 2019A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's DiseaseAn Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's DiseaseBehcet DiseaseDrug: InfliximabJanssen Korea, Ltd., KoreaNot recruiting19 Years75 YearsAll33Phase 3Korea, Republic of
17EUCTR2014-002108-25-DE17/06/201511 April 2016Study to test whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment of active Behçet’s disease (oral ulcers). This study also tests how well the body tolerates apremilast. The study is conducted in several centers in different countries.A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF SUBJECTS WITH ACTIVE BEHÇET’S DISEASESUBJECTS WITH ACTIVE BEHÇET’S DISEASE
MedDRA version: 18.1 Level: LLT Classification code 10004212 Term: Behcet's disease System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Apremilast
Product Code: CC-10004
Pharmaceutical Form: Tablet
INN or Proposed INN: APREMILAST
CAS Number: 608141-41-9
Current Sponsor code: CC-10004
Other descriptive name: APREMILAST
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Apremilast
Product Code: CC-10004
Pharmaceutical Form: Tablet
INN or Proposed INN: APREMILAST
CAS Number: 608141-41-9
Current Sponsor code: CC-10004
Other descriptive name: APREMILAST
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Product Name: Apremilast
Product Code: CC-10004
Pharmaceutical Form: Tablet
INN or Proposed INN: APREMILAST
CAS Number: 608141-41-9
Current Sponsor code: CC-10004
Other descriptive name: APREMILAST
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Celgene CorporationAuthorisedFemale: yes
Male: yes
204Phase 3France;United States;Turkey;Israel;Germany;Japan;Italy;Korea, Republic of
18NCT02258867November 201418 January 2016Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease UveitisA Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease UveitisBehcet's Disease UveitisDrug: Placebo;Drug: GevokizumabXOMA (US) LLCNot recruiting18 YearsN/ABoth4Phase 3United States
19NCT01988506January 6, 201427 August 2018Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory DiseasesInduction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic ApproachRheumatoid Arthritis;Ankylosing Spondylitis;Systemic Lupus Erythematosus;Psoriasis;Behcet's Disease;Wegener's Granulomatosis;Takayasu's Disease;Crohn's Disease;Ulcerative Colitis;Autoimmune Hepatitis;Sclerosing Cholangitis;Gougerot-sjögren;Idiopathic Thrombocytopenic Purpura;Systemic SclerosisDrug: Interleukin 2Assistance Publique - Hôpitaux de ParisIltoo PharmaRecruiting18 YearsN/AAll132Phase 2France
20JPRN-UMIN0000124692013/12/027 October 2019Comparison of Adalimumab and Steroid in Intestinal Behcet's diseaseComparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle StudyIntestinal Behcet's diseaseSubcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously.
Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately
Castle Study GroupRecruiting15years-oldNot applicableMale and Female50Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT02620618January 201314 December 2015Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical StudyIntravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical StudyBehçet's Disease;UveitisDrug: Intravitreal InfliximabCairo UniversityNot recruitingN/AN/ABoth20Phase 1/Phase 2
22NCT01965145November 201211 June 2018Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease UveitisBehcet's UveitisDrug: Gevokizumab;Drug: PlaceboServierNot recruiting18 YearsN/AAll84Phase 3Korea, Republic of;United Kingdom
23EUCTR2012-001125-27-DE24/09/201212 October 2015Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisA randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis EYEGUARD TM -BBehçet’s disease uveitis
MedDRA version: 17.1 Level: LLT Classification code 10071139 Term: Behcet's uveitis System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: Gevokizumab
Product Code: S78989
Pharmaceutical Form: Solution for injection
INN or Proposed INN: gevokizumab
CAS Number: 1129435-60-4
Current Sponsor code: S78989
Other descriptive name: XOMA 052
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 60-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Institut de Recherches Internationales ServierNot RecruitingFemale: yes
Male: yes
44Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Germany;Tunisia;China;Korea, Republic of
24NCT01532570January 201219 October 2017Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special LesionsTo Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650Behcet's Disease;Behcet Syndrome;Neuro-Behcet's DiseaseDrug: TA-650Mitsubishi Tanabe Pharma CorporationNot recruiting16 Years75 YearsAll18Phase 3Japan
25EUCTR2010-024152-29-DE02/09/201119 March 2012An open-label study to evaluate efficacy and tolerability of Canakinumab in patients with Behçet Disease who do not respond to standard treatment (Eine offene Studie zur Wirksamkeit und Verträglichkeit von Canakinumab bei Patienten mit Morbus Behçet, die auf die übliche Behandlung nicht ansprechen)Canakinumab for Behçet`s Disease Resistant to Standard Treatment (CanBeDisT) - CanBeDisTBehçet`s Disease
MedDRA version: 14.0 Level: PT Classification code 10004213 Term: Behcet's syndrome System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Ilaris
Product Name: Ilaris
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: CANAKINUMAB
CAS Number: 914613-48-2
University Hospital of TübingenAuthorisedFemale: yes
Male: yes
10Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT01441076September 201116 December 2017Anakinra for Behcet s DiseaseA Pilot Study of Anakinra in Behcet's Disease (BD)Autoimmune Connective Tissue Disorder;Immune System DiseasesDrug: AnakinraNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Not recruiting18 Years65 YearsAll6Phase 1/Phase 2United States
27NCT00931957October 201019 February 2015Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's DiseaseEtanercept: Single Blind Control Study in Ocular Manifestations of Behcet's DiseaseBehcet Syndrome;Uveal DiseaseDrug: Etanercept, Methotrexate, PrednisoloneTehran University of Medical SciencesWyeth is now a wholly owned subsidiary of PfizerRecruiting16 Years60 YearsBoth80N/AIran, Islamic Republic of
28NCT01243671October 201019 October 2017A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's DiseaseA Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's DiseaseIntestinal Behçet's DiseaseBiological: AdalimumabAbbVie (prior sponsor, Abbott)Eisai Co., Ltd.Not recruiting15 YearsN/AAll20Phase 3Japan
29NCT01211977August 27, 201016 December 2017A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's DiseaseA Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD)Muckle Wells Syndrome;Autoinflammatory;Behcet's DiseaseDrug: XOMA 052National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Not recruiting18 YearsN/AAll0Phase 1/Phase 2United States
30NCT01306955February 201019 February 2015The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's DiseaseThe Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot StudyBehcet's DiseaseDrug: methylorednisolone;Other: dextrose water 5%Tehran University of Medical SciencesRecruiting10 Years70 YearsBoth34Phase 4Iran, Islamic Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2009-013901-33-AT12/11/200919 March 2012A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303E1Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0 Level: LLT Classification code 10036370 Term: Posterior uveitis
Product Name: AIN457
Product Code: AIN457
Pharmaceutical Form: Powder for solution for infusion
Pharmaceutical form of the placebo: Powder for solution for infusion
Route of administration of the placebo: Subcutaneous use
Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes
112Germany;France;Spain;Greece;Austria
32EUCTR2009-011237-27-HU15/10/20092 March 2015A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy - C2303Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
MedDRA version: 12.0 Level: LLT Classification code 10036370 Term: Posterior uveitis
Product Name: AIN457
Product Code: AIN457
Pharmaceutical Form: Powder for solution for injection
Pharmaceutical form of the placebo: Powder for solution for injection
Route of administration of the placebo: Subcutaneous use
Novartis Pharma Services AgNot RecruitingFemale: yes
Male: yes
112France;Hungary;Greece;Spain;Austria;Germany;Italy
33NCT00866359August 1, 200916 December 2017A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet DiseaseA Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet DiseaseBehcet SyndromeDrug: Apremilast (CC-10004);Drug: PlaceboCelgeneNot recruiting18 YearsN/AAll111Phase 2United States;Turkey
34NCT00720928July 200819 February 2015Flucinolone Acetonide Implant for Treating Refractory Ocular Behcet's DiseaseA Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's DiseaseOcular Behcet's Disease,;Non-Infectious Uveitis;Refractory UveitisDrug: flucinolone acetonideAsan Medical CenterSamsung Medical Center;Seoul National University Hospital;Kyunghee University Medical CenterRecruiting18 YearsN/ABoth15Phase 4Korea, Republic of
35NCT00550498December 200723 November 2015Stem Cell Transplantation in Ocular Lesions of Behcet's DiseasePhase 1 Study of Bone Marrow - Derived Stem Cell in the Treatment of Ocular Lesions of Behcet's DiseaseRetinitis;Behcet's SyndromeBiological: Autologous Stem Cell TransplantationTehran University of Medical SciencesNot recruiting16 YearsN/ABoth5Phase 1Iran, Islamic Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT00483184April 200619 October 2017Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's DiseasePhase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's DiseaseBehcet Syndrome;Behcet Disease;Mucocutaneous UlcerationBiological: Veldona,Nobel PharmaceuticalsAmarillo Biosciences, Inc.Not recruiting18 Years75 YearsAll84Phase 2Turkey
37NCT00664599April 200619 February 2015Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's DiseaseEffect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study)Behcet's SyndromeDrug: Rituximab;Drug: Cytotoxic CombinationTehran University of Medical SciencesHoffmann-La RocheNot recruiting16 YearsN/ABoth20Phase 2Iran, Islamic Republic of
38NCT00167583November 200411 June 2018Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB)Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal VasculitisDrug: Cyclosporin A;Drug: Interferon-alpha2aUniversity Hospital TuebingenNot recruiting18 Years75 YearsAll37Phase 3Germany
39NCT00278512August 20038 August 2016Hematopoietic Stem Cell Support in VasculitisHigh Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's SyndromeVasculitisBiological: Autologous Stem Cell Transplant;Biological: Allogeneic Stem Cell TransplantNorthwestern UniversityNot recruiting16 Years60 YearsBoth7Phase 1United States
40NCT00700297August 200219 February 2015Colchicine Randomized Double-Blind Controlled Crossover Study in Behcet's DiseaseA Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet`s DiseaseBehcet's SyndromeDrug: Colchicine;Drug: PlaceboTehran University of Medical SciencesNot recruiting14 Years60 YearsBoth169Phase 2Iran, Islamic Republic of
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT00001865July 199919 February 2015HAT in Eye Complications of Behcet's DiseaseA Study to Investigate the Safety and Efficacy of HAT to Treat the Ocular Complications Related to Behcet's DiseaseBehcet's Syndrome;Retinal Disease;UveitisDrug: DaclizumabNational Eye Institute (NEI)Not recruitingN/AN/ABoth26Phase 2United States

先頭へ